vTv Therapeutics (VTVT) Starts Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis

March 18, 2021 4:08 PM EDT
Get Alerts VTVT Hot Sheet
Price: $2.75 +1.10%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

vTv Therapeutics Inc. (Nasdaq: VTVT) announced the initiation of a mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. The phase 1 study will test the hypothesis that treatment with vTv’s TTP399, a liver-selective glucokinase activator, will not result in the increased production of ketones, a precursor to ketoacidosis, which can lead to hospitalization in patients with type 1 diabetes.

Despite advances in insulin therapy and monitoring technologies, many patients with type 1 diabetes still do not achieve acceptable glycemic control. Poor glycemic control has resulted in a global increase in hospitalizations for people with type 1 diabetes caused by hypoglycemia or diabetic ketoacidosis. TTP399 previously demonstrated improvement in glycemic control without increased incidence of diabetic ketoacidosis or hypoglycemia in a three-month phase 2 study in patients with type 1 diabetes.

“Developing a drug that does not increase the risk of diabetic ketoacidosis or, even better, has the potential to reduce that risk while improving glycemic control and reducing the risk of hypoglycemia would be a win for patients with type 1 diabetes,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “This would represent a substantial improvement over insulin administration alone.”

The Company continues to push forward with the development of TTP399 in type 1 diabetes and is on track to initiate the first pivotal study later this year.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Related Entities

Twitter, Definitive Agreement